Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba317f76dccaa8a745268d8c0d9af9cb6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba317f76dccaa8a745268d8c0d9af9cb6 NCIT_P378 "NCI" @default.
- Ba317f76dccaa8a745268d8c0d9af9cb6 type Axiom @default.
- Ba317f76dccaa8a745268d8c0d9af9cb6 annotatedProperty IAO_0000115 @default.
- Ba317f76dccaa8a745268d8c0d9af9cb6 annotatedSource NCIT_C114498 @default.
- Ba317f76dccaa8a745268d8c0d9af9cb6 annotatedTarget "An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation." @default.